# Vedolizumab iv PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vedolizumab-iv

> The next catalyst for vedolizumab iv, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Sep to Dec 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | vedolizumab iv |
| Codes | MLN0002 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease), [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Crohn's Disease (CD)](https://sec-api.dev/indications/crohn-s-disease-cd), [Moderately to Severely Active Ulcerative Colitis](https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Moderately to Severely Active Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT03221036

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease (CD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04779320 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-13 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04779320

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease (CD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04779320 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-13 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04779320

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Moderately to Severely Active Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT03221036

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100289 (A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06100289

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100289 (A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06100289

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05837897 (A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05837897

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05837897 (A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05837897

## Same indication

- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09), [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vedolizumab-iv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vedolizumab iv PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vedolizumab-iv

```bibtex
@misc{secapidev_pdufa_vedolizumab_iv_20261116,
  title        = {Vedolizumab iv PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vedolizumab-iv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vedolizumab_iv_20261116","title":"Vedolizumab iv PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vedolizumab-iv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
